Fresenius SE & Co. KGaA buy Stipica
Start price
09.11.20
/
50%
€34.41
Target price
09.11.21
€40.00
Performance (%)
18.27%
End price
02.11.21
€40.70
Summary
This prediction ended on 02.11.21 with a price of €40.70. The prediction had a final performance of 18.27%. Dividends of €0.88 are taken into consideration when calculating the performance. Stipica has 50% into this predictionFresenius is a German healthcare company listed on the Frankfurt and New York stock exchanges under the symbol FSNUF. The company is primarily engaged in the production and distribution of medical devices, pharmaceuticals, and services related to renal dialysis, critical care, and hospital operations. With over 290,000 employees and operations in more than 100 countries, Fresenius is one of the largest healthcare providers in the world. The company has experienced steady growth over the years, driven by its innovative product portfolio, strategic acquisitions, and a focus on operational efficiency.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Fresenius SE & Co. KGaA | 5.012% | 5.012% | 3.501% | -30.874% |
| iShares Core DAX® | -1.785% | -1.250% | 11.664% | 12.714% |
| iShares Nasdaq 100 | -2.154% | 0.300% | 37.531% | 41.653% |
| iShares Nikkei 225® | -4.028% | -3.746% | 17.142% | 0.393% |
| iShares S&P 500 | -1.969% | 0.307% | 25.617% | 40.084% |
According to Stipica what are the pros and cons of Fresenius SE & Co. KGaA for the foreseeable future?
Pros
Could be very worthwhile Investment >20% year
Market Leader or Top 3
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Fair valuation
High dividend yield expected
Standard Investments for future growth
Higher EBIT margin than peer group
Cons
Increased challenges to pay loans and raise capital